Alzamend Neuro 2019 Annual Report Form 1-K

Alzamend Neuro, Inc. filed its Form 1-K annual report for fiscal year ended April 30, 2019, detailing its business focused on developing immunotherapy approaches to prevent, treat, and cure Alzheimer's disease. The company was formed in February 2016 to acquire and commercialize patented intellectual property addressing the neurological condition through novel therapeutic mechanisms.